Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

被引:866
作者
Tentori, Francesca [1 ]
Blayney, Margaret J. [1 ]
Albert, Justin M. [1 ]
Gillespie, Brenda W. [2 ]
Kerr, Peter G. [3 ]
Bommer, Juergen [4 ]
Young, Eric W. [5 ]
Akizawa, Tadao [6 ]
Akiba, Takashi [7 ]
Pisoni, Ronald L. [1 ]
Robinson, Bruce M. [1 ]
Port, Friedrich K. [1 ]
机构
[1] Arbor Res Collaborat Hlth, Ann Arbor, MI 48103 USA
[2] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Monash Univ, Monash Med Ctr, Clayton, Vic, Australia
[4] Heidelberg Univ, Heidelberg, Germany
[5] Univ Michigan, Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA
[6] Showa Univ, Tokyo, Japan
[7] Tokyo Womens Med Univ, Tokyo, Japan
关键词
hemodialysis; mineral metabolism; cardiovascular disease; guidelines; Dialysis Outcomes and Practice Patterns Study (DOPPS);
D O I
10.1053/j.ajkd.2008.03.020
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Abnormalities in serum calcium, phosphorus, and parathyroid hormone (PTH) concentrations are common in patients with chronic kidney disease and have been associated with increased morbidity and mortality. No clinical trials have been conducted to clearly identify categories of calcium, phosphorus, and PTH levels associated with the lowest mortality risk. Current clinical practice guidelines are based largely on expert opinions, and clinically relevant differences exist among guidelines across countries. We sought to describe international trends in calcium, phosphorus, and PTH levels during 10 years and identify mortality risk categories in the Dialysis Outcomes and Practice Patterns Study (DOPPS), an international study of hemodialysis practices and associated outcomes. Study Design: Prospective cohort study. Participants: 25,588 patients with end-stage renal disease on hemodialysis therapy for longer than 180 days at 925 facilities in DOPPS I (1996-2001), DOPPS II (2002-2004), or DOPPS III (2005-2007). Predictors: Serum calcium, album in-corrected calcium (Ca-AIb), phosphorus, and PTH levels. Outcomes: Adjusted hazard ratios for all-cause and cardiovascular mortality calculated using Cox models. Results: Distributions of mineral metabolism markers differed across DOPPS countries and phases, with lower calcium and phosphorus levels observed in the most recent phase of DOPPS. Survival models identified categories with the lowest mortality risk for calcium (8.6 to 10.0 mg/dL), Ca-Alb (7.6 to 9.5 mg/dL), phosphorus (3.6 to 5.0 mg/dL), and PTH (101 to 300 pg/mL). The greatest risk of mortality was found for calcium or Ca-Alb levels greater than 10.0 mg/dL, phosphorus levels greater than 7.0 mg/dL, and PTH levels greater than 600 pg/mL and in patients with combinations of high-risk categories of calcium, phosphorus, and PTH. Limitations: Because of the observational nature of DOPPS, this study can only indicate an association between mineral metabolism categories and mortality. Conclusions: Our results provide important information about mineral metabolism trends in hemodialysis patients in 12 countries during a decade. The risk categories identified in the DOPPS cohort may be relevant to efforts at international harmonization of existing clinical guidelines for mineral metabolism.
引用
收藏
页码:519 / 530
页数:12
相关论文
共 37 条
[1]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[2]  
CANNATAANDIA JB, 2000, NEPHROL DIAL TRAN S5, V15, pS43
[3]   Albumin-corrected calcium and ionized calcium in stable haemodialysis patients [J].
Clase, CM ;
Norman, GL ;
Beecroft, ML ;
Churchill, DN .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (11) :1841-1846
[4]   PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis [J].
Danese, MD ;
Kim, J ;
Doan, QV ;
Dylan, M ;
Griffiths, R ;
Chertow, GM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (01) :149-156
[5]   On the evolving nature of understanding dialysis-related disorders [J].
Eknoyan, G ;
Lindberg, JS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :S1-S3
[6]  
Elder Grahame, 2006, Nephrology (Carlton), V11 Suppl 1, pS230, DOI 10.1111/j.1440-1797.2006.00508.x
[7]   Managing bone parameters in dialysis patients: International guideline conflicts [J].
Faull, Randall J. .
SEMINARS IN DIALYSIS, 2007, 20 (03) :191-194
[8]   Hypocalcemia, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Hu, LQ ;
ODea, R ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (05) :386-393
[9]  
Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
[10]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483